Imunon, Inc. Share Price & Technical Analysis
IMNN · $2.20 (+2.33%)
Healthcare / Biotechnology
$2.20
+2.33%
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-24% return in May, 67% avg return in past 3 year May month.
-53% return in 2026, 14% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -13% | -3% | -9% | -3% | -24% | – | – | – | – | – | – | – | -53% |
| 25 | -6% | 4% | 13% | -20% | 201% | -71% | -31% | -17% | -14% | -12% | -11% | -7% | 29% |
| 24 | -25% | 119% | 39% | -22% | 11% | -19% | 9% | -20% | -8% | -12% | -12% | 8% | 67% |
| 23 | 19% | -11% | -10% | 5% | -10% | 6% | -2% | -2% | -20% | 3% | -8% | -23% | -53% |
| 22 | -16% | -35% | 10% | -41% | -16% | -25% | 18% | 0% | -20% | -12% | -6% | -2% | -145% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$10.79M
P/E ratio
—
52W high
$41.22
52W low
$2.08
Volume
33,686
Beta
2.03
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Imunon, Inc. share price today?
- Imunon, Inc. (IMNN) last traded around $2.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IMNN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IMNN. Download the app for real-time alerts.
- How can I analyze Imunon, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.